Skip to main content

Table 3 Frequency of adverse events in the two groups

From: Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial

Adverse events Trearment group
memantine+sertraline placebo+sertraline p-value
N % N %
Muscle pain 2 5.7 2 6.7 0.87
Headache 2 5.7 2 6.7 0.87
Diarhea 1 2.9 0 0 0.35
Constipation 0 0 0 0 1
Decreased libido 5 14.3 3 10 0.60
Decreased appetite 5 14.3 3 10 0.60
Lightheadness 1 2.9 0 0 0.35
Palpitation 0 0 1 3.3 0.28
Insomnia 3 8.6 0 0 0.10
Vomiting 3 8.6 1 3.3 0.38